Compare APPF & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPF | CYTK |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.0B |
| IPO Year | 2015 | 2004 |
| Metric | APPF | CYTK |
|---|---|---|
| Price | $219.53 | $63.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | ★ $310.75 | $84.81 |
| AVG Volume (30 Days) | 254.4K | ★ 1.8M |
| Earning Date | 01-29-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.16 | N/A |
| EPS | ★ 5.58 | N/A |
| Revenue | ★ $906,294,000.00 | $87,211,000.00 |
| Revenue This Year | $21.89 | $339.72 |
| Revenue Next Year | $18.58 | $79.08 |
| P/E Ratio | $39.29 | ★ N/A |
| Revenue Growth | 18.88 | ★ 2609.26 |
| 52 Week Low | $190.24 | $29.31 |
| 52 Week High | $326.04 | $70.98 |
| Indicator | APPF | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 51.02 |
| Support Level | $209.22 | $62.25 |
| Resistance Level | $226.03 | $65.38 |
| Average True Range (ATR) | 8.04 | 2.93 |
| MACD | -0.43 | 0.06 |
| Stochastic Oscillator | 33.99 | 64.02 |
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.